Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients

Vildagliptin Has a Neutral Association With Dementia Risk in Type 2 Diabetes Patients

Background and aimsAnimal studies suggested that vildagliptin might exert a beneficial effect on cognitive function. The present study evaluated whether the use of vildagliptin in patients with type 2 diabetes mellitus might affect dementia risk.MethodsThe database of Taiwan’s National Health Insura...

Full description

Bibliographic Details
Main Author:	Chin-Hsiao Tseng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-04-01
Series:	Frontiers in Endocrinology
Subjects:	vildagliptin dementia diabetes mellitus pharmacoepidemiology Taiwan
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2021.637392/full

Similar Items

Pioglitazone Has a Null Association with Inflammatory Bowel Disease in Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng
Published: (2022-12-01)

Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study
by: Chin-Hsiao Tseng, et al.
Published: (2022-10-01)

The Risk of Multiple Myeloma Is Reduced in Metformin Initiators: A Retrospective Cohort Study in Taiwanese Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng
Published: (2022-11-01)

Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients
by: Chin-Hsiao Tseng
Published: (2023-05-01)

The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin
by: Chin-Hsiao Tseng
Published: (2023-02-01)

Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis
by: Chin-Hsiao Tseng
Published: (2022-05-01)

Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng
Published: (2021-08-01)

Metformin Use Is Associated With a Lower Incidence of Hospitalization for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng, et al.
Published: (2021-02-01)

Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis
by: Chin‐Hsiao Tseng
Published: (2019-11-01)

Effect of Metformin on Lower Urinary Tract Symptoms in Male Patients with Type 2 Diabetes Mellitus: A Retrospective Cohort Study in Taiwan
by: Chin-Hsiao Tseng
Published: (2023-07-01)

Human Insulin Therapy Is Associated With an Increased Risk of Lung Cancer: A Population-Based Retrospective Cohort Study
by: Chin-Hsiao Tseng, et al.
Published: (2019-07-01)

Metformin Is Associated with a Lower Incidence of Benign Brain Tumors: A Retrospective Cohort Study in Patients with Type 2 Diabetes Mellitus
by: Chin-Hsiao Tseng
Published: (2021-09-01)

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report
by: Serhat Sayin, et al.
Published: (2018-03-01)

Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke
by: Dong‐Yi Chen, et al.
Published: (2020-01-01)

Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan
by: Tseng Chin-Hsiao
Published: (2013-01-01)

Thiazolidinedione Use Is Associated with a Borderline Lower Risk of Multiple Myeloma and a Significantly Lower Risk of Death in Patients with Type 2 Diabetes Mellitus in Taiwan
by: Chin-Hsiao Tseng
Published: (2023-08-01)

Comparison of Vildagliptin-Metformin and Glimepiride-Metformin Treatments in Type 2 Diabetic Patients
by: Hyun Jeong Jeon, et al.
Published: (2011-10-01)

EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2013-06-01)

Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes mellitus in the Pakistani population
by: Asima Khan, et al.
Published: (2022-08-01)

Efficacy and pathogenetic justification for the use of vildagliptin in patients with type 2 diabetes mellitus
by: V.I. Pankiv
Published: (2019-10-01)

Metformin and Risk of Hypertension in Taiwanese Patients With Type 2 Diabetes Mellitus
by: Chin‐Hsiao Tseng
Published: (2018-07-01)

Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study
by: Chin-Hsiao Tseng
Published: (2023-01-01)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
by: Hara Kousoulakou, et al.
Published: (2017-09-01)

Diabetes, insulin use and Helicobacter pylori eradication: a retrospective cohort study
by: Tseng Chin-Hsiao
Published: (2012-05-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Vildagliptin: a new oral treatment for type 2 diabetes mellitus
by: Chantal Mathieu, et al.
Published: (2008-12-01)

Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients
by: Chin-Hsiao Tseng, et al.
Published: (2023-07-01)

Mild acute pancreatitis with vildagliptin use
by: Ravikant Saraogi, et al.
Published: (2012-01-01)

Budget impact of vildagliptin
by: Orietta Zaniolo, et al.
Published: (2008-09-01)

Vildagliptin: optimal control in type 2 diabetes mellitus treatment
by: Alexander Sergeevich Ametov
Published: (2015-12-01)

Acute Effects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial
by: Alessandra Schiappacassa, et al.
Published: (2020-10-01)

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study
by: Sol Batule, et al.
Published: (2022-05-01)

Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing
by: Chen-Hung Lee, et al.
Published: (2023-04-01)

Vildagliptin Treatment on the Portal Venous Pressure and Hepatosteatosis in Patients with Type 2 Diabetes Mellitus
by: Cumali KARATOPRAK, et al.
Published: (2018-01-01)

The efficacy of therapy with DPP-4 inhibitors combined with insulin in patients with type 2 diabetes mellitus
by: Alexander Sergeevich Ametov, et al.
Published: (2011-12-01)

A Randomized, Two-Treatments, Two-Periods, Crossover, Open label, Laboratory-Blind, Single Dose Bioequivalence Study between Vildagliptin/Metformin 50 mg/1000 mg Film Coated Tablets (Sensityn®) and Galvusmet® 50 mg/1000 mg Film Coated Tablets in healthy adults under fed conditions
by: Shiekmydeen J., et al.
Published: (2023-10-01)

Nanofibrous Vildagliptin/PLGA Membranes Accelerate Diabetic Wound Healing by Angiogenesis
by: Chen-Hung Lee, et al.
Published: (2022-11-01)

PROSPECTS OF NEPHROPROTECTION AGAINST TYPE 2 DIABETES USING THE DPP-4 INHIBITOR VILDAGLIPTIN
by: V. K. Bayrasheva, et al.
Published: (2017-12-01)

EFFECT OF PHARMACOLOGICAL PRECONDITIONING WITH INCRETINOMIMETICS EXENATIDE AND VILDAGLIPTIN ON THE SURVIVAL OF ISCHEMIC TISSUES
by: Alla Tarasova, et al.
Published: (2017-12-01)